• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis

byMinjee Kim
April 20, 2023
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission compared to placebo.

2. Majority of adverse events were mild-to-moderate in nature with no reported fatalities.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ulcerative colitis is a chronic, autoimmune disease of the gastrointestinal tract that affects many patients worldwide. Etrasimod, a sphingosine 1-phosphate receptor modulator, may play a role in treating ulcerative colitis, although little is known to date. This study is an amalgamation of two independent, randomized controlled trials, ELEVATE UC 12 and ELEVATE UC 52, that aimed to assess the safety and efficacy of etrasimod in patients with moderate-to-severe ulcerative colitis. ELEVATE UC 12 assessed induction with etrasimod at week 12 while ELEVATE UC 52 comprised a 12-week induction period followed by a 40-week maintenance period. The primary efficacy endpoint was the proportion of patients who achieved clinical remission at weeks 12 and 52. According to study results, more patients in the etrasimod group achieved clinical remission compared to placebo after 12 weeks of induction and this was sustained up to 52 weeks. Additionally, the etrasimod group reported greater improvements in endoscopic appearance, symptom control, and corticosteroid-free remission. This study was strengthened by data from two independent trials, thus adding to the validity and generalizability of findings.

Click to read the study in The Lancet

Relevant Reading: Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

RELATED REPORTS

Food compounds associated with disease activity in inflammatory bowel disease 

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

In-depth [randomized-controlled trial]: Between Jun 13, 2019, and Jan 28, 2021, 821 patients and 606 patients were assessed for eligibility in ELEVATE UC 52 and ELEVATE UC 12, respectively. Included were patients ≥ 16 years old with endoscopy-confirmed moderate-to-severe active ulcerative colitis and a known history of inadequate response to pharmacotherapy. Patients were randomized to receive daily oral estrasimod 2 mg or placebo. The primary efficacy endpoint of clinical remission was achieved among significantly greater patients in the etrasimod group compared to placebo (25% vs. 15%, p=0.026) in ELEVATE UC 12 after induction for 12 weeks. Similarly, estrasimod improved clinical remission at weeks 12 (27% in etrasimod vs. 7% in placebo, p<0.0001) and week 52 (32% in etrasimod vs. 7% in placebo, p<0.0001) among patients in the ELEVATE UC 52 group. Adverse events were comparable between both groups and there were no treatment-related fatalities. Findings from this study suggest that etrasimod is effective for induction and maintenance in patients with ulcerative colitis.

 

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: etrasimodIBDinflammatory bowel diseasesphingosine 1-phosphate receptor modulatorUCUlcerative Colitisulcerative colitis treatment
Previous Post

Wellness Check: Spirituality

Next Post

#VisualAbstract: Subclinical coronary atherosclerosis is associated with increased risk of myocardial infarction

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Food compounds associated with disease activity in inflammatory bowel disease 

June 25, 2025
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

June 9, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

May 14, 2025
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
Next Post
#VisualAbstract: Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis

#VisualAbstract: Subclinical coronary atherosclerosis is associated with increased risk of myocardial infarction

Increased risk of stillbirth recurrence after a previous stillbirth

Spirituality may influence the aggressiveness of end-of-life treatments in cancer patients

Testosterone replacement in male cancer survivors helps improve body composition

Prostate cancer overscreening persists despite guideline changes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.